Lupus-scleroderma syndrome induced by ethosuximide.
Features of both systemic lupus erythematosus and scleroderma developed in a young Chinese girl while on multiple anticonvulsant therapy. These were reversed after withdrawal of the drugs. Readministration of ethosuximide for control of epilepsy caused a relapse with predominant sclerodermatous features. These clinical signs again resolved after ethosuximide withdrawal.
D000293:Adolescent; D000740:Anemia / Q000188:drug therapy; D004830:Epilepsy, Tonic-Clonic / Q000188:drug therapy*; D005013:Ethosuximide / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced* / Q000175:diagnosis; D010634:Phenobarbital / Q000627:therapeutic use; D010672:Phenytoin / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D012595:Scleroderma, Systemic / Q000139:chemically induced* / Q000175:diagnosis
D005013:Ethosuximide; D010672:Phenytoin; D011239:Prednisolone; D010634:Phenobarbital